A Phase 2 interventional study of Psilocybin in Post Traumatic Stress Disorder, PTSD and Chronic PTSD, sponsored by Unity Health Toronto. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Unity Health Toronto · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing psilocybin in Stress Disorders, Post-Traumatic — 13 open to participants now, 16 under way, 3 of them phase 3. Psilocybin · Stress Disorders, Post-Traumatic.
Among the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic, this one is the 15th largest by planned enrollment, is one of 7 that started in 2026, is one of 10 in phase 2, reaches primary completion later than 11 of the 15 other live ones, and was the 9th registered.
2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →13 of the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic are open now, in 5 countries. Recruiting first, the newest first:
COMPASS Pathways · Sites in United States, Canada
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18–75
Sunstone Medical · Sites in United States
Ages 18+ · Women only
University of New Mexico · Sites in United States
Ages 18–89
Khyber Medical University Peshawar · Sites in Pakistan
Ages 18–60
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 11 · Phase 3 4
First in 2022; this study’s year is marked. 7 started in 2026.
This study's planned enrollment of 15 is below the median of 69 across 2,203 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 33 across the 20 interventional studies. Of the 3 that completed or were terminated, 2 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 20 have an industry lead sponsor. The 10 most frequent:
Unity Health Toronto is the lead sponsor of 447 studies on the registry; 81 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Unity Health Toronto has 4 studies filed under Stress Disorders, Post-Traumatic — fewer than ten, so there is no comparison to draw.
5 of the studies testing psilocybin in Stress Disorders, Post-Traumatic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07703722Phase 3Khyber Medical University PeshawarEffect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder | 2027-10-22 |
| NCT07737054Tel-Aviv Sourasky Medical CenterTrauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD | 2026-12-01 |
| NCT06888128Baylor College of MedicineState-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma | 2026-12-15 |
| NCT07506395University of New MexicoGroup Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder | 2027-05-01 |
| NCT06902974Sunstone MedicalPsilocybin-Assisted Therapy for Sexual Assault-Related PTSD | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label trial evaluating feasibility, tolerability, safety and efficacy of psilocybin assisted cognitive processing therapy for chronic Posttraumatic Stress Disorder (PTSD).
Current front-line treatments for Posttraumatic stress disorder (PTSD) are ineffective for up to half of patients, with serious medical and societal consequences. It is imperative to improve the efficacy of front-line treatment options, such as cognitive processing therapy (CPT). CPT is an effective treatment for PTSD, including when delivered intensively (i.e., multiple sessions over 7 days). However, a substantial proportion of patients continue to meet criteria for PTSD or have residual PTSD symptoms post-treatment. Psilocybin-assisted CPT may be a potential solution, as preliminary evidence supports the potential of psilocybin to alleviate symptoms of PTSD.
Fifteen participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days. Participants will complete clinician-administered scales, self-reported mental health questionnaires, and use a wearable device. After the 1-week interventional period, participants will enter a 12-weeks follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of psilocybin 25mg + Massed cognitive processing therapy
Drug: Psilocybin
Participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days.
Feasibility and tolerability
Recruitment rate, withdrawal rate, adherence rate, data completion rate, percentage of participants with severe adverse events.
Time frame: Up to 16 weeks
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score
The CAPS-5 is a semi-structured clinical interview used to assess index history of DSM-5-defined traumatic event exposure, including the most distressing event, time since exposure, and total number of exposures, as well as frequency and severity of posttraumatic stress symptoms.
Time frame: Up to 16 weeks
Posttraumatic stress disorder Checklist-5 (PCL-5)
The PCL-5 is self-report questionnaire in which respondents indicate the presence and severity of PTSD symptoms, derived from the DSM-5 symptoms of PTSD.
Time frame: Up to 16 weeks
Patient Health Questionnaire-9 (PHQ-9)
The PHQ-9 is a self-rated measure of depressive symptom severity in the past two weeks. Each of the nine items is rated on a Likert scale, ranging from 0 (not at all) to 3 (nearly every day), and summed for a total score between 0 (no symptoms) to 27 (most severe).
Time frame: Up to 16 weeks
Generalized Anxiety Disorder Scale, 7-item (GAD-7)
Total score ranges from 0 to 21; a higher score denotes greater symptom severity.
Time frame: Up to 16 weeks
Dissociative Experiences Scale II (DES-II)
The Dissociative Experiences Scale II is a 28-item, self-report measure of dissociative experiences.
Time frame: Up to 13 weeks
Pittsburgh Sleep Quality Index (PSQI)
The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval.
Time frame: Up to 13 weeks
World Health Organization Well-Being Index, 5-item (WHO-5)
The WHO-5 is a measure of overall well-being, rated on a scale of 0 to 25, with higher scores denoting higher quality of life.
Time frame: Up to 16 weeks
Quality of relationships inventory (QRI)
The QRI is a self-report questionnaire used to determine the quality relationships consisting of 25 items that are evaluated on a 4-point Likert scale ranging from 1 = not true to 4 = almost always true.
Time frame: Up to 13 weeks
Inventory of psychosocial functioning (IPF)
The IPF is an 80-item self-report instrument measuring PTSD-related functional impairment in the past 30 days.
Time frame: Up to 13 weeks
Posttraumatic Maladaptive Beliefs Scale (PMBS)
The PMBS is a 15-item scale that was developed to measure maladaptive beliefs about life circumstances that may occur following trauma exposure.
Time frame: Up to 13 weeks
Brief Experiential Avoidance Questionnaire (BEAQ)
The BEAQ is a 15-item self-report measure of experiential avoidance.
Time frame: Up to 13 weeks
24-items Multidimensional Psychological Flexibility Inventory (MPFI-24)
The MPFI-24 is a 24-item self-report scale developed to assess the specific components of psychological flexibility and inflexibility.
Time frame: Up to 13 weeks
Working Alliance Inventory- Short Form (WAI-SF)
The WAI-SF is a patient-rated measure of the alliance between a therapist and client.
Time frame: Up to Day 7
Difficulties in Emotion Regulation Scale-Short Form (DERS-SF)
The DERS-SF is an 18-item measure used to identify emotional regulation issues in adults.
Time frame: Up to 13 weeks
Self-Compassion Scale-Short Form (SCS-SF)
The SCS-SF is a 12-item self-report measure of self-compassion.
Time frame: Up to 13 weeks
Psychological Insight Questionnaire (PIQ)
The PIQ is a 23-item self-report measure of acute experiences of insight (e.g. awareness into emotions, behaviors, beliefs, memories, or relationships) after taking a psychedelic.
Time frame: Up to Day 3
Emotional Breakthrough Inventory (EBI)
The EBI is a measure of emotional release/breakthrough experienced during the acute psychedelic state.
Time frame: Up to Day 3
Altered States of Consciousness Rating Scale (ASC)
The ASC measures altered states of consciousness.
Time frame: Up to Day 3
Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ)
The APEQ is a psychometric self-report tool for measuring aspects of the acute psychedelic experience that are associated with longer-term changes in psychological flexibility.
Time frame: Up to Day 3
Childhood Trauma Questionnaire-short form (CTQ-SF)
Time frame: Screening
Effect on digital physiological passive data collected through the use of a wearable device
Example: sleep, activity
Time frame: Up to 16 weeks
Plan to share: No
Started Jun 2026 (actual). Primary completion is estimated for Jan 2028, 19 months after the start.
Of 87 non-industry phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 59. This study's planned 19 months is below that.
Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Jan 2027 → Jan 2028 and completion Jan 2027 → Jun 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Psilocybin
Stress Disorders, Post-Traumatic →